Restricted accessReview articleFirst published online 2025
Pathological and Immunohistochemical Features of Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomy Oblastic Differentiation (Malignant Triton Tumor) in the Context of the Malignant Peripheral Nerve Sheath Tumor Spectrum
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas arising from Schwann cells or neurofibromas, comprising ∼10% of soft tissue sarcomas. Found in 8% to 13% of neurofibromatosis type 1 patients, they typically show spindle cells expressing S100 and SOX10. Some display heterologous differentiation (bone, cartilage, vessels, or glands). When rhabdomyosarcomatous features are present, they are called malignant peripheral nerve heath tumor with heterologous rhabdomyoblastic differentiation (malignant triton tumors), which are more prone to recurrence, metastasis, and worse outcomes. Epithelial differentiation does not affect prognosis. Despite advances in understanding MPNST biology, many pathophysiological mechanisms remain unclear. This review highlights their histopathology, focusing on malignant triton tumor.
LanzettaIPedrazzoliPRifaldiF, et al.Malignant triton tumor: a narrative review of current evidence and a single center experience. Ann Case Report. 2024;9:1878. https://doi.org/10.29011/2574-7754.101878
2.
PatriziSMieleEFalconeL, et al.Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population. Clin Epigenetics. 2024;16(1):9. doi: 10.1186/s13148-023-01621-7
3.
Camacho-PartidaIGOrtiz-HidalgoC. El diagnóstico histológico y la inmunohistoquímica de las neoplasias de la vaina del nervio periférico. Patología Rev Latinoam. 2017;55(4):445-464.
MiettinenMMAntonescuCRFletcherCDM, et al.Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1-10. doi: 10.1016/j.humpath.2017.05.010
6.
RechbergerJSMillesiEPowerEA, et al.Shaping our understanding of malignant peripheral nerve sheath tumor: a bibliometric analysis of the 100 most-cited articles. World Neurosurg. 2024;184:293-302. e11. doi: 10.1016/j.wneu.2024.01.054.
7.
SalehMDibABeainiS, et al.Neurofibromatosis type 1 system-based manifestations and treatments: a review. Neurol Sci. 2023;44(6):1931-1947. doi: 10.1007/s10072-023-06680-5
8.
SimanshuDKNissleyDVMcCormickF. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17-33. doi: 10.1016/j.cell.2017.06.009
9.
YaoCZhouHDongY, et al.Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management. Cancers (Basel). 2023;15(4):1077. doi: 10.3390/cancers15041077
GuedesFBrownRSTorrão-JuniorFJLBarbosaDANRavaniniGAGAmorimRMP. Pediatric peripheral nerve tumors: clinical and surgical aspects. Childs Nerv Syst. 2019;35(12):2289-2297. doi: 10.1007/s00381-019-04306-w
12.
ThwayKFisherC. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 2014;18(2):109-116. doi: 10.1016/j.anndiagpath.2013.10.007
13.
KarMDeoSVShuklaNK, et al.Malignant peripheral nerve sheath tumors (MPNST)—clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol. 2006;4:55. doi: 10.1186/1477-7819-4-55
14.
KamranSCHowardSAShinagareAB, et al.Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. Eur J Surg Oncol. 2013;39(1):46-52. doi: 10.1016/j.ejso.2012.09.001
15.
Le GuellecSDecouvelaereAVFilleronT, et al.Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French sarcoma group database. Am J Surg Pathol. 2016;40(7):896-908. doi: 10.1097/PAS.0000000000000655
16.
KasprianGAmannGPanotopoulosJ, et al.Peripheral nerve tractography in soft tissue tumors: a preliminary 3-tesla diffusion tensor magnetic resonance imaging study. Muscle Nerve. 2015;51(3):338-345. doi: 10.1002/mus.24313
17.
Hidalgo CODosamantes AC. Perineuroma maligno (tumor maligno de vaina nerviosa periférica, perineural). Estudio inmunohistoquímico de un tumor poco frecuente, utilizando EMA, GLUT1 y Claudina-1, como marcadores de diferenciación perineural. Rev Esp Patol 2006;39: 105-111.
18.
AbdelzaherEElwanyAAmrSA. Malignant peripheral nerve sheath tumour with perineurial differentiation and hyaline eosinophilic globules (thanatosomes): a rare tumour. Malays J Pathol. 2018;40(3):355-358.
19.
GuoALiuAWeiLSongX. Malignant peripheral nerve sheath tumors: differentiation patterns and immunohistochemical features—a mini-review and our new findings. J Cancer. 2012;3:303-309. doi: 10.7150/jca.4179
MassonPMartinJF. Rhabdomyomes des nerfs. Bull. Assoc. Fr. Cancer. 1938;27:751-767.
22.
MassonP. Libman anniversary volumes. In: LibmanE, ed. Recklinghausen’s neurofibromatosis, sensory neuroma and motor neuroma. Vol. 2. The International Press; 1932:793-802.
23.
LocatelliP. Formation de membres surnuméraires. C R Assoc Anat. 1925;20:279-282.
24.
Ortiz-HidalgoC. Pathology and mythology. Am J Dermatopathol. 1992;14(6):572-575. doi: 10.1097/00000372-199212000-00017
25.
SingerM. Developing cell systems and their control. In: RoseSM (ed.) Nervous mechanisms in the regeneration of body parts in vertebrates. The Ronald Press Co; 1960:115-133.
26.
MassonP. Human tumors: histology, diagnosis, and technique. 2nd ed. Wayne State University Press; 1970, p. 1107-1109.
27.
Soria-CéspedesDMartínez-MadrigalFMéndez-SashidaPOrtiz-HidalgoC. Meduloepitelioma pigmentado maligno intraocular. Presentación de dos casos. Rev Esp Patol. 2009;42(3):225-229.
ZouCSmithKDLiuJ, et al.Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014-1022. doi: 10.1097/SLA.0b013e3181a77e9a.
30.
SeresRHameedHMcCabeMGRussellDLeeATJ. The multimodality management of malignant peripheral nerve sheath tumours. Cancers (Basel). 2024;16(19):3266. doi: 10.3390/cancers16193266
31.
Guedes-CorrêaJF. Cardoso RSV. Immunohistochemical markers for schwannomas neurofibromas and malignant peripheral nerve sheath tumors—what can the recent literature tell us?Arq Bras Neurocir. 2018;37:105-112.
32.
KangYPekmezciMFolpeALErsenAHorvaiAE. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014;27(1):55-61. doi: 10.1038/modpathol.2013.115
33.
ShimadaSTsuzukiTKurodaM, et al.Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int. 2007;57(2):60-67. doi: 10.1111/j.1440-1827.2006.02059.x
34.
WatanabeTOdaYTamiyaSKinukawaNMasudaKTsuneyoshiM. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology. 2001;39(2):187-197. doi: 10.1046/j.1365-2559.2001.01176.x
35.
KosemehmetogluKVranaJAFolpeAL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009;22(7):872-878. doi: 10.1038/modpathol.2009.47
36.
HuiPLiNJohnsonC, et al.HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. Mod Pathol. 2005;18(11):1519-1526. doi: 10.1038/modpathol.3800464
37.
LyskjaerILindsayDTiraboscoR, et al.H3k27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. J Pathol. 2020;252(2):151-164. doi: 10.1002/path.5507
38.
OwoshoAAEstiloCLHurynJMChiPAntonescuCR. A clinicopathologic study of head and neck malignant peripheral nerve sheath tumors. Head Neck Pathol. 2018;12(2):151-159. doi: 10.1007/s12105-017-0841-y
39.
LeeWTeckieSWiesnerT, et al.PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227-1232. doi: 10.1038/ng.3095
40.
Cortes-CirianoISteeleCDPiculellK, et al.Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13(3):654-671. doi: 10.1158/2159-8290.CD-22-0786
41.
ItoYKohashiKEndoM, et al.Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation. Virchows Arch. 2021;479(6):1233-1244. doi: 10.1007/s00428-021-03189-0
42.
PemovALiHPresleyWWallaceMRMillerDT. Genetics of human malignant peripheral nerve sheath tumors. Neurooncol Adv. 2019;2(Suppl 1):i50-i61. doi: 10.1093/noajnl/vdz049
43.
ParkerNAAl-ObaidiADeutschJM. SMARCB1/INI1-deficient tumors of adulthood. F1000Res. 2020;9:662. doi: 10.12688/f1000research.24808.2.
44.
RekhiBKosemehmetogluKTezelGGDervisogluS. Clinicopathologic features and immunohistochemical spectrum of 11 cases of epithelioid malignant peripheral nerve sheath tumors, including INI1/SMARCB1 results and BRAF V600E analysis. APMIS. 2017;125(8):679-689. doi: 10.1111/apm.12702
45.
OdeyemiOOOzawaMGCharvilleGW. CDX2 expression in malignant peripheral nerve sheath tumour: a potential diagnostic pitfall associated with PRC2 inactivation. Histopathology. 2022;80(6):995-1000. doi: 10.1111/his.14626
46.
PekmezciMReussDEHirbeAC, et al.Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol. 2015;28(2):187-200. doi: 10.1038/modpathol.2014.109
47.
WoodruffJMGodwinTAErlandsonRASusinMMartiniN. Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor. Am J Surg Pathol. 1981;5(8):733-744.
48.
BrennanB. Malignant peripheral nerve sheath tumor: the need to get it right first time around. Pediatr Blood Cancer. 2018;65(2). doi:10.1002/pbc.26852
49.
MartinECoertJHFluckeUE, et al.A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2020;124:77-87. doi: 10.1016/j.ejca.2019.10.014
